Combined Er:YAG And Nd:YAG Laser Protocol For Treatment Of Peri-Implantitis
- Conditions
- Peri-Implantitis
- Registration Number
- NCT03819075
- Lead Sponsor
- Luis Monteiro
- Brief Summary
A laser treatment for periimplantitis using two different wavelengths (Er:YAG and Nd:YAG) will be compared to standard treatment in a randomized clinical trial.
- Detailed Description
The general aim of this study is to evaluate the clinical outcome of the treatment of peri-implantitis using a combination of a Er:YAG and Nd:YAG laser protocol or using a conventional mechanical treatment in patients with a diagnosis of peri-implantitis.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 62
- at least one implant with peri-implantitis
- no serious mobility of the implants
- written informed consent of the voluntary participant in the study
- availability of participant for control visits for a follow-up of at least 12 months without interruptions
- serious systematic disease
- pregnancy
- current use of photosensitive drugs, bisphosphonate medication or antibiotics
- patients who do not want to follow post treatment recommendation of oral hygiene and follow-up visits
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proportion of participants with treatment success 6 months Treatment success defined as implant survival with the absence of peri-implant probing depths (PD) greater than 5 mm with concomitant bleeding/suppuration and absence of progression of peri-implant bone loss.
- Secondary Outcome Measures
Name Time Method Bleeding on probing 12 months evaluated as present if bleeding was evident within 30 s after probing, or absent, if no bleeding was noticed within 30 s after probing.
Plaque index 12 months (PI)
Probing depth 12 months measured from the mucosal margin to the bottom of the pocket.
Mucosal recession 12 months measured from the mucosal margin to the bottom of the pocket.
Clinical attachment level gain 12 months Difference in clinical attachment level at baseline and follow up.
Quality of life questionnaire 12 months Oral Health Impact Profile-14 on the scale from 0 to 56 with higher scores indicating a poorer oral health-related quality of life.
Trial Locations
- Locations (1)
Instituto Universitário de Ciências da Saude, CESPU
🇵🇹Porto, Portugal
Instituto Universitário de Ciências da Saude, CESPU🇵🇹Porto, PortugalLuis MonteiroContact+351 919120226luis.monteiro@iucs.cespu.pt